22
Pharmacokinetics isthe study ofthe processesthataffectdrug distribution and the rate ofchange ofdrug concentrationsw ithin various regionsofthe body. These processesare also collectively referred to as ADM ET fordrug a dsorption, d istribution, m etabolism , e xcretion, and t oxicity. W e also need to distinguish pharm acokineticsfrom sim ilarterm s. Therefore, pharmaceutics concernsthe form ulation and preparation of the drug to achieve a desired drug availability w ithin the body, pharmacodynamics isconcerned w ith the tim e course ofthe treatm ent response thatresultsfrom a given drug, and the actual physiological response thatresultsfrom a drug isthe subjectof pharmacology. The application ofpharm acokineticsto toxic/hazardoussubstancesis called toxicokinetics .

FDA Drug Approval Process

  • Upload
    swann

  • View
    77

  • Download
    0

Embed Size (px)

DESCRIPTION

FDA Drug Approval Process. Pharmacokinetics. Therapeutic Window. Pharmacodynamics. Effect of treatment. Graded response saturates and may be described by. C is what comes from the PK analysis hence one then knows the treatment response from equation at left. Drug Entry. - PowerPoint PPT Presentation

Citation preview

Page 1: FDA Drug Approval Process

Pharmacokinetics is the study of the processes that affect drug distribution and the rate of change of drug concentrations within various regions of the body. These processes are also collectively referred to as ADMET for drug adsorption, distribution, metabolism, excretion, and toxicity.

We also need to distinguish pharmacokinetics from similar terms. Therefore, pharmaceutics concerns the formulation and preparation of the drug to achieve a desired drug availability within the body, pharmacodynamics is concerned with the time course of the treatment response that results from a given drug, and the actual physiological response that results from a drug is the subject of pharmacology.

The application of pharmacokinetics to toxic/hazardous substances is called toxicokinetics.

Page 2: FDA Drug Approval Process

FDA Drug Approval Process

Page 3: FDA Drug Approval Process
Page 4: FDA Drug Approval Process
Page 5: FDA Drug Approval Process

Pharmacokinetics

Page 6: FDA Drug Approval Process
Page 7: FDA Drug Approval Process

Therapeutic Window

Page 8: FDA Drug Approval Process

PharmacodynamicsEffect oftreatment

Page 9: FDA Drug Approval Process

Graded response saturates and may be described by

CC

CEE

50

maxC is what comes from the PKanalysis hence one then knowsthe treatment response fromequation at left

Page 10: FDA Drug Approval Process

Drug Entry

Page 11: FDA Drug Approval Process
Page 12: FDA Drug Approval Process

1. Prefer plasma drug concentration since it is quicker and not interfered by hemolysis and release of RBC proteins2. Drug concentration as measured is usually the total plasma concentration or what is known as the unbound and bound drug concentration3. Drug effect, distribution, and elimination is due to unbound drug concentration4. fu is the fraction unbound = Cu/Ctotal and is usually constant so either Cu or Ctotal can be used in a PK analysis, just be sure to know what you are using

Page 13: FDA Drug Approval Process

Splanchnic circulation takes the drug from the GI tractdirectly to the liver for what is called first pass elimination,which can significantly reduce the amount of drug thatis available for a given dose.

Page 14: FDA Drug Approval Process
Page 15: FDA Drug Approval Process

Diffusion through the lipid bilayer depends on the solubility of the drug.

Environment is aqueous, lipid, then aqueous in the cell

Standard way of describing the lipid solubility of a drug is by the logPWhich is also the octanal/water partition coefficient which is defined as:

W

OWO C

CKP 10/10 logloglog

logP > 0 means the drug is more soluble in octanal than in water and aretherefore called lipophilic drugs

logP < 0 means the drug is less soluble in octanol than in water and aremore hydrophilic

Optimal logP for passive diffusion across the lipd bilayer of cells is around2-3

Page 16: FDA Drug Approval Process

Increasing lipophilicity

Page 17: FDA Drug Approval Process
Page 18: FDA Drug Approval Process

Passive transport: rate = P S C

Carrier mediatedTransport: Cf

K

VKCffor

CfK

CfVrate U

ttU

Ut

U

maxmax ,

Note only the unbound drug is transported, bound drug is usuallywith albumin which is too big

Page 19: FDA Drug Approval Process
Page 20: FDA Drug Approval Process

Perfusion limited - Tissue membranes present no resistance to drug transport

Permeability limited – membranes of the capillaries and cells limit transport

Page 21: FDA Drug Approval Process

Perfusion rate limited

Permeability-limited

Page 22: FDA Drug Approval Process

Permeability ratelimited